Menopause and risk of diabetes in the Diabetes Prevention Program

Menopause

Volumn 18, Issue 8, 2011, Pages 857-868

  Kim, Catherine ^a   Edelstein, Sharon L ^b   Crandall, Jill P ^c   Dabelea, Dana ^d   Kitabchi, Abbas E ^e   Hamman, Richard F ^f   Montez, Maria G ^g   Perreault, Leigh ^h   Foulkes, Mary A ^b   Barrett Connor, Elizabeth ⁱ  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d Food Science and Human Nutrition   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g University of Texas Health Science Center   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Impaired glucose tolerance; Menopause; Oophorectomy; Women; Words: Diabetes

Indexed keywords

METFORMIN;

ADULT; ARTICLE; DIABETES MELLITUS; FEMALE; GLUCOSE INTOLERANCE; HIGH RISK PATIENT; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MENOPAUSE; OVARIECTOMY; POSTMENOPAUSE; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION;

ADULT; ANALYSIS OF VARIANCE; BODY MASS INDEX; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH PROMOTION; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MENOPAUSE; METFORMIN; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PREDIABETIC STATE; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; RISK ASSESSMENT; WOMEN'S HEALTH;

EID: 80051544600     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31820f62d0     Document Type: Article

References (28)

1. Sowers M, Derby C, Jannausch M, Torrens J, Pasternak R. Insulin resistance, hemostatic factors, and hormone interactions in pre-and perimenopausal women: SWAN. J Clin Endocrinol Metab 2003;88: 4904-4910. (Pubitemid 37357542)
2. Ding E, Song Y, Malik V, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes. JAMA 2006;295: 1288-1299.
3. Kanaya A, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2003;138:1-9.
4. Janssen I, Powell L, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome. Arch Intern Med 2008;168: 1568-1575.
5. Soriguer F, Morcillo S, Hernando V, et al. Type 2 diabetes mellitus and other cardiovascular risk factors are no more common during menopause. Menopause 2009;16:817-821.
6. Mishra G, Carrigan G, Brown W, Barnett A, Dobson A. Short-term weight change and the incidence of diabetes in mid-life. Diabetes Care 2007;30:1418-1424.
7. Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: the role of the ovary? Menopause 2011;18:30-43.
8. Knowler W, Barrett-Connor E, Fowler S, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. (Pubitemid 34437694)
9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31:S55-S60.
10. Santoro N, Brockwell S, Johnson J, et al. Helping midlife women predict the onset of final menses: SWAN, the Study of Women's Health Across the Nation. Menopause 2007;14:415-424.
11. Kitabchi A, Temprosa M, Knowler W, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: effects of lifestyle intervention and metformin. Diabetes 2005;54:2404-2414. (Pubitemid 41134269)
12. Mather K, Funahashi T, Matsuzawa Y, et al. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008;57:980-986.
13. Haffner S, Temprosa M, Crandall J, et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005;54:1566-1572.
14. Diabetes Prevention Program Research Group. Lipid, lipoproteins, Creactive protein, and hemostatic factors at baseline in the Diabetes Prevention Program. Diabetes Care 2005;28:2472-2479.
15. Diggle P, Liang K, Zeger S. Analysis of Longitudinal Data. New York: Oxford University Press, 1994.
16. Salley K, Wickham E, Cheang K, Essah P, Karjane N, Nestler J. Glucose intolerance in polycystic ovary syndromeVa position statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007; 92:4546-4556. (Pubitemid 350223423)
17. Casson P, Toth M, Johnson J, Stanczyk F, Casey C, Dixon M. Correlation of serum androgens with anthropometric and metabolic indices in healthy, nonobese postmenopausal women. J Clin Endocrinol Metab 2010;95:4276-4282.
18. Lemieux S, Lewis G, Ben-Chetrit A, Steiner G, Greenblatt E. Correction of hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels. J Clin Endocrinol Metab 1999; 84:4278-4282. (Pubitemid 30644230)
19. Crandall J, Schade D, Ma Y, et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci 2006;61:1075-1081. (Pubitemid 44727217)
20. Stefanick M. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the U.S. Food and Drug Administration. Am J Med 2005;118:64-73.
21. Kanaya A, Grady D, Barrett-Connor D. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus. Arch Intern Med 2002;162:1737-1745.
22. Manson J, Rimm E, Colditz G, et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin dependent diabetes mellitus. Ann Epidemiol 1992;2:665-673.
23. Margolis K, Bonds D, Rodabough R, et al. Effects of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004;47:1175-1187. (Pubitemid 39093314)
24. Espeland M, Hogan P, Fineberg S, et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Diabetes Care 1998;21:1589-1595. (Pubitemid 28449793)
25. Bonds D, Lasser N, Qi L, et al. The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. Diabetologia 2006;49:459-468. (Pubitemid 43277868)
26. Friday K, Dong C, Fontenot R. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2001;86:48-52. (Pubitemid 32109774)
27. Andersson B, Mattsson L, Hahn L, et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:638-643. (Pubitemid 27068643)
28. Samaras K, Hayward C, Sullivan D, Kelly R, Campbell L. Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study. Diabetes Care 1999;22:1401-1407. (Pubitemid 29418230)